Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 25, 2008

View Archived Issues

BASF tenders offer to acquire Ciba

Results from PEARL trial with lasofoxifene presented at the ASBMR meeting

AC-100 promotes cartilage regeneration and repair in experimental models in goats

BTG makes recommended all share offer for Protherics

Transdel enrolls first patient in Ketotransdel phase III registration study

ReNeuron presents business update ahead of its 2008 Annual General Meeting

Array BioPharma reports development of soft calineurin inhibitors for atopic dermatitis

Maxygen and Astellas sign agreement for MAXY-4 in autoimmune diseases and transplant rejection

FDA requests 3-month extension on PDUFA deadline to review NovaDel's Zolpimist

Trillium secures new financing to fund development of TTI-1612

SIGA receives additional USD 20 million from the NIAID to develop antiviral ST-246

iBioPharma selects plant-made influenza vaccine as first clinical development candidate

p38alpha inhibitor developed at Abbott demonstrates beneficial activity in arthritis models

Allergy Therapeutics presents positive results from phase III Pollinex Quattro Ragweed study

Bristol-Myers Squibb to commence cash tender offer for ImClone Systems

CytRx completes Innovive acquisition and provides pipeline update

New pharmaceutical aids imparted by Emisphere

EMEA expands orphan medicinal product status for Neo-Bladder Augment

Recent patents describe novel agents for endocrine disorders

Novel asthma/COPD drug candidate AZD-1419 nominated for development

Cangene files MAA in Europe for HepaGam B solution for infusion or injection

Recent patents disclose novel antiinfective agents

Durect grants worldwide rights to Alpharma for Eladur pain patch

Genmab completes recruitment in phase II ofatumumab trial

Labopharm submits NDA to the FDA for DDS-04A to treat major depression

MethylGene and Celgene convert to milestone arrangement for MGCD-0103

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...